Cannabidivarin

Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH₂ units).

Cannabidivarin

Clinical data
ATC code	none
Identifiers
IUPAC name 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl) cyclohex-2-enyl)-5-propylbenzene-1,3-diol
CAS Number	24274-48-4 N
PubChem CID	11601669
DrugBank	DB14050 N
ChemSpider	21106275 Y
UNII	I198VBV98I
KEGG	C20217
ChEMBL	ChEMBL2387742
CompTox Dashboard (EPA)	DTXSID70893921
ECHA InfoCard	100.236.933
Chemical and physical data
Formula	C19H26O2
Molar mass	286.415 g·mol−1
3D model (JSmol)	Interactive image
SMILES C=C(C)[C@H]2CCC(\C)=C/[C@@H]2c1c(O)cc(CCC)cc1O
InChI InChI=1S/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m1/s1 Y Key:REOZWEGFPHTFEI-CVEARBPZSA-N Y
NY (what is this?)  (verify)

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.^[1][2][3]

CBDV demonstrated anticonvulsant in rodent models in a single published study.^[4] It was identified for the first time in 1969 by Vollner et al.^[5]

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)^[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.^[7] GW has begun several Phase-2 trials for adult epilepsy,^[8] for childhood epilepsy and for Prader-Willi Syndrome.^[9][10]

See also

• List of investigational analgesics